<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04970498</url>
  </required_header>
  <id_info>
    <org_study_id>M2021111</org_study_id>
    <nct_id>NCT04970498</nct_id>
  </id_info>
  <brief_title>Application of MRI in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer</brief_title>
  <official_title>Application of MRI Quantitative Parameters in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rectal cancer patients who received neoadjuvant chemoradiotherapy in Peking University Third&#xD;
      Hospital in 2021 are divided into acute myelosuppression group, chronic myelosuppression&#xD;
      group and normal group. The differences of magnetic resonance parameters between the groups&#xD;
      were compared. The risk identification model of acute and chronic myelosuppression after&#xD;
      neoadjuvant chemoradiotherapy was established by clinical risk factors and quantitative&#xD;
      parameters of magnetic resonance imaging, and the prediction efficiency of the model was&#xD;
      evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients with locally advanced rectal cancer diagnosed in Peking University Third&#xD;
      Hospital and undergoing neoadjuvant chemoradiotherapy were collected. The basic information&#xD;
      of patients (including age, sex, BMI, TNM stage of rectal cancer (T2, T3 stage)) was&#xD;
      collected. The blood routine was collected before radiotherapy, 1 week, 2 weeks and 90 days&#xD;
      after radiotherapy. MRI including T1WI, DWI sequence and IDEAL-IQ sequence before&#xD;
      radiotherapy, 1-2 weeks after radiotherapy and 90 days after radiotherapy were performed, and&#xD;
      the corresponding parameters were obtained. The white blood cell values and quantitative&#xD;
      parameters of magnetic resonance (including T1WI, DWI signal intensity (b = 1000) and proton&#xD;
      density fat fraction (PDFF) of sacrilium and proximal femur were collected. Patients were&#xD;
      divided into acute myelosuppression group and non-acute myelosuppression group according to&#xD;
      blood routine results 14 days after radiotherapy, and chronic myelosuppression group and&#xD;
      non-chronic myelosuppression group according to blood routine results 90 days after&#xD;
      radiotherapy. The magnetic resonance parameters difference between 1-2 weeks after&#xD;
      radiotherapy and before radiotherapy, and the magnetic resonance parameters difference&#xD;
      between 90 days after radiotherapy and before radiotherapy were calculated. By comparing the&#xD;
      differences of clinical risk factors and quantitative parameters of MRI between the two&#xD;
      groups, the meaningful variables were screened out, and the risk identification model of&#xD;
      acute and chronic myelosuppression was established.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of IDEAL-IQ sequence of MRI</measure>
    <time_frame>1-2 weeks after radiotherapy</time_frame>
    <description>The differences of PDFF(%) between the acute myelosuppression group and no suppression group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of T1WI sequence of MRI</measure>
    <time_frame>1-2 weeks after radiotherapy</time_frame>
    <description>The differences of T1WI signal intensity（IU） between the acute myelosuppression group and no suppression group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of DWI sequence of MRI</measure>
    <time_frame>1-2 weeks after radiotherapy</time_frame>
    <description>The differences of DWI signal intensity（IU）between the acute myelosuppression group and no suppression group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of ADC map of MRI</measure>
    <time_frame>1-2 weeks after radiotherapy</time_frame>
    <description>The differences of ADC value（mm^2/s) between the acute myelosuppression group and no suppression group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of IDEAL-IQ sequence of MRI</measure>
    <time_frame>90 days after radiotherapy</time_frame>
    <description>The differences of PDFF(%) between the chronic myelosuppression group and no suppression group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of T1WI sequence of MRI</measure>
    <time_frame>90 days after radiotherapy</time_frame>
    <description>The differences T1WI signal intensity（IU）between the chronic myelosuppression group and no suppression group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of DWI sequence of MRI</measure>
    <time_frame>90 days after radiotherapy</time_frame>
    <description>The differences of DWI signal intensity（IU）between the chronic myelosuppression group and no suppression group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of ADC map of MRI</measure>
    <time_frame>90 days after radiotherapy</time_frame>
    <description>The differences of ADC value（mm^2/s) between the chronic myelosuppression group and no suppression group</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Rectal Cancer Stage II</condition>
  <condition>Rectal Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>acute myelosuppression group</arm_group_label>
    <description>WBC &lt;4.0×10^9 14 days after radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chronic myelosuppression group</arm_group_label>
    <description>WBC &lt;4.0×10^9 90 days after radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no myelosuppression group</arm_group_label>
    <description>WBC &gt;4.0×10^9 during radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI including T1WI, DWI sequence and IDEAL-IQ sequence before radiotherapy, 1-2 weeks after radiotherapy and 90 days after radiotherapy were performed</description>
    <arm_group_label>acute myelosuppression group</arm_group_label>
    <arm_group_label>chronic myelosuppression group</arm_group_label>
    <arm_group_label>no myelosuppression group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood routine test</intervention_name>
    <description>The blood routine was collected before radiotherapy, 1 week, 2 weeks and 90 days after radiotherapy.</description>
    <arm_group_label>acute myelosuppression group</arm_group_label>
    <arm_group_label>chronic myelosuppression group</arm_group_label>
    <arm_group_label>no myelosuppression group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        From February 2021 to August 2022, patients with locally advanced rectal cancer were&#xD;
        treated with neoadjuvant chemoradiotherapy in the Third Hospital of Peking University&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  From February 2021 to August 2022, patients with locally advanced rectal cancer were&#xD;
             treated with neoadjuvant chemoradiotherapy in the Third Hospital of Peking University.&#xD;
&#xD;
          -  There were blood routine before radiotherapy, 1 week, 2 weeks and 90 days after&#xD;
             radiotherapy, and MRI examination including routine MRI sequence and IDEAL-IQ sequence&#xD;
             before radiotherapy, 1-2 weeks and 90 days after radiotherapy.&#xD;
&#xD;
          -  Each patient used the same chemotherapy regimen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with metabolic bone diseases such as hyperparathyroidism and Cushing's&#xD;
             syndrome.&#xD;
&#xD;
          -  Patients with history of pelvic radiotherapy or systemic chemotherapy.&#xD;
&#xD;
          -  Patients with leukocytes below 4.0×10^9/L or long-term severe anemia before&#xD;
             radiotherapy.&#xD;
&#xD;
          -  Patients with tumor bone metastases; patients with pelvic trauma, fracture, and&#xD;
             infectious diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ning Lang, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>宁 朗, Professor</last_name>
    <phone>13501241339</phone>
    <email>13501241339@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ning 朗, Professor</last_name>
    <phone>13501241339</phone>
    <email>13501241339@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University third hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100089</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Lang</last_name>
      <phone>+861082265571</phone>
      <email>langning800129@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>July 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 11, 2021</last_update_submitted>
  <last_update_submitted_qc>July 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rectal Cancer</keyword>
  <keyword>Myelosuppression</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>IDEAL-IQ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

